1. Home
  2. LFCR vs AGEN Comparison

LFCR vs AGEN Comparison

Compare LFCR & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lifecore Biomedical Inc.

LFCR

Lifecore Biomedical Inc.

HOLD

Current Price

$5.68

Market Cap

143.9M

Sector

Health Care

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$3.38

Market Cap

147.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LFCR
AGEN
Founded
1986
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
143.9M
147.4M
IPO Year
1996
1999

Fundamental Metrics

Financial Performance
Metric
LFCR
AGEN
Price
$5.68
$3.38
Analyst Decision
Buy
Buy
Analyst Count
3
2
Target Price
$6.00
$14.50
AVG Volume (30 Days)
179.1K
588.7K
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
100.00
EPS
N/A
1.02
Revenue
$557,559,000.00
$42,877,086.00
Revenue This Year
N/A
$107.63
Revenue Next Year
$5.04
N/A
P/E Ratio
N/A
$3.32
Revenue Growth
6.36
89.95
52 Week Low
$3.63
$2.71
52 Week High
$8.98
$7.34

Technical Indicators

Market Signals
Indicator
LFCR
AGEN
Relative Strength Index (RSI) 62.57 49.26
Support Level $4.75 $2.93
Resistance Level $5.92 $4.72
Average True Range (ATR) 0.28 0.20
MACD 0.06 0.02
Stochastic Oscillator 78.09 68.37

Price Performance

Historical Comparison
LFCR
AGEN

About LFCR Lifecore Biomedical Inc.

Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: